Journal
JOURNAL OF OTOLARYNGOLOGY
Volume 32, Issue 4, Pages 259-261Publisher
B C DECKER INC
DOI: 10.2310/7070.2003.41631
Keywords
cyclic guanosine monophosphate; nasal patency; phosphodiesterase 5; sildenafil
Categories
Ask authors/readers for more resources
Objective: Sildenafil (Viagra; Pfizer), a phosphodiesterase inhibitor, promotes penile erection through increased intracellular cyclic guanine monophosphate (a second messenger) in response to nitric oxide (a first messenger) release following sexual stimulation. Nitric oxide is involved in nasal vasodilation, secretion, and mucociliary clearance. The aim of this study was to assess the effect of sildenafil on nasal patency. Design: Pilot study. Setting: Teaching hospital. Methods: Nasal patency was assessed by a visual analogue score and by measurement of the peak nasal inspiratory flow (PNIF) in five subjects before and after administration of sildenafil. Main Outcome Measures: Visual analogue score and PNIF. Results: There was a significant increase in the subjective sensation of nasal obstruction.(p = .003; -9.6 +/- 2.7, -15.4 to -3.7 [mean +/- SEM, 95% CI]) and a significant reduction of PNIF (p < .001; 70.7 +/- 13.2, 43.1 to 98.3). Conclusions: This pilot study suggests that nasal patency may be reduced following the administration of sildenafil. The role of phosphodiesterase inhibitors in nasal physiology merits further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available